Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer

International Journal of Cancer

Volumn 130, Issue 2, 2012, Pages 377-387

  Tanaka, Sonosuke ^a   Hattori, Noboru ^a   Ishikawa, Nobuhisa ^a   Shoda, Hiroyasu ^a   Takano, Atsushi ^a   Nishino, Ryohei ^a   Okada, Morihito ^a   Arihiro, Koji ^a   Inai, Kouki ^a   Hamada, Hironobu ^b,c   Yokoyama, Akihito ^d   Kohno, Nobuoki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d KOCHI UNIVERSITY   (Japan)

Author keywords

biomarker; cell surface antigen; KL 6; lung cancer; MUC1

Indexed keywords

GLYCOPROTEIN; KREBS VON DEN LUNGEN 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KREBS VON DEN LUNGEN 6 BLOOD LEVEL; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; MUCIN-1; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 83655192111     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26007     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E,. Japanese Joint Committee of Lung Cancer Registry. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008; 3: 46-52.
3. Parkin DM,. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
4. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M,. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-21.
5. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-97.
6. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-27.
7. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M,. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988; 18: 203-16.
8. Kohno N, Inoue Y, Hamada H, Fujioka S, Fujino S, Yokoyama A, Hiwada K, Ueda N, Akiyama M,. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer Suppl 1994; 8: 81-3.
9. Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K,. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol 1997; 17: 501-7.
10. Ohyabu N, Hinou H, Matsushita T, Izumi R, Shimizu H, Kawamoto K, Numata Y, Togame H, Takemoto H, Kondo H, Nishimura S,. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. J Am Chem Soc 2009; 131: 17102-9.
11. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M,. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68-73.
12. Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, Yokoyama A, Hamada H, Fujioka S, Hiwada K,. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993; 148: 637-42.
13. Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, Hirasawa Y, Hiwada K,. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 1680-4.
14. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N,. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165: 378-81.
15. Nakashima T, Yokoyama A, Ohnishi H, Hamada H, Ishikawa N, Haruta Y, Hattori N, Tanigawa K, Kohno N,. Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome. J Intern Med 2008; 263: 432-9.
16. Inata J, Hattori N, Yokoyama A, Ohshimo S, Doi M, Ishikawa N, Hamada H, Kohno N,. Circulating KL-6/MUC1 mucin carrying sialyl Lewis(a) oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma. Int J Cancer 2007; 120: 2643-9.
17. Ishikawa N, Hattori N, Yokoyama A, Tanaka S, Nishino R, Yoshioka K, Ohshimo S, Fujitaka K, Ohnishi H, Hamada H, Arihiro K, Kohno N,. Usefulness of monitoring the circulating Krebs von den Lungen-6 (KL-6) levels to predict the clinical outcome of patients with advanced non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Int J Cancer 2008; 122: 2612-20.
18. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M,. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161: 589-94.
19. Kondo K, Kohno N, Yokoyama A, Hiwada K,. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res 1998; 58: 2014-2019.
20. Doi M, Yokoyama A, Kondo K, Ohnishi H, Ishikawa N, Hattori N, Kohno N,. Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping. Cancer Sci 2006; 97: 420-9.
21. Aoki R, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F, Kohno N,. MUC-1 expression as a predictor of the curative endoscopic treatment of submucosally invasive colorectal carcinoma. Dis Colon Rectum 1998; 41: 1262-72.
22. Nagata S, Tanaka S, Haruma K, Kitadai Y, Yoshihara M, Shimamoto F, Kohno N, Chayama K,. MUC1 and cathepsin D expression in early colorectal carcinoma showing V type pit pattern. Int J Oncol 2001; 19: 665-72.
23. Kurosaki M, Izumi N, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T, Asahina Y, Uchihara M, Miyake S,. Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. Hepatol Res 2005; 33: 250-7.
24. Hiraga Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F, Kohno N,. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998; 55: 307-19.
25. Kimura T, Tanaka S, Haruma K, Sumii K, Kajiyama G, Shimamoto F, Kohno N,. Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol 2000; 16: 55-64.
26. Yamasaki H, Ikeda S, Okajima M, Miura Y, Asahara T, Kohno N, Shimamoto F,. Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors. Int J Oncol 2004; 24: 107-13.
27. Tang W, Inagaki Y, Kokudo N, Guo Q, Seyama Y, Nakata M, Imamura H, Sano K, Sugawara Y, Makuuchi M,. KL-6 mucin expression in carcinoma of the ampulla of Vater: association with cancer progression. World J Gastroenterol 2005; 11: 5450-4.
28. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M,. Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol 2006; 12: 54-9.
29. Perey L, Hayes DF, Maimonis P, Abe M, O'Hara C, Kufe DW,. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res 1992; 52: 2563-3568.
30. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC,. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001; 91: 1973-1982.
31. Nagai S, Takenaka K, Sonobe M, Ogawa E, Wada H, Tanaka F,. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol 2006; 1: 46-51.
32. Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y,. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004; 10: 8363-70.
33. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, Murakami H, Takeshima Y, Inai K, Nishimura H, Tsuchiya E, Kohno N, et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005; 65: 9176-84.
34. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Tanaka S, Yasui W, Takeshima Y, Inai K, Nishimura H, Tsuchiya E, Kohno N, et al. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci 2006; 97: 737-45.
35. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, et al. Cancer-Testis Antigen, LY6K is a Serologic Biomarker and a Therapeutic Target for Lung and Esophageal Carcinomas. Cancer Res 2007; 67: 11601-11.
36. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009; 69: 6694-703.
37. Travis W, Brambilla E, Müller-Hermelink HK, Harris CC,. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004. 344 p.
38. Sobin LH, Wittekind C, eds. TNM classification of malignant tumors, 5th edn., New York: John Wiley, 1997. 227 p.
39. Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, Decamp MM,. Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer. Cancer 2009; 115: 1059-69.
40. Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, Bando M, Sugiyama Y, Totani Y, Ishizaki T, Ichiyasu H, Suga M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006; 11: 164-8.
41. Hollingsworth MA, Swanson BJ,. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 4: 45-60.
42. Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Yonezawa S,. Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology 2004; 44: 147-55.
43. Ohgami A, Tsuda T, Osaki T, Mitsudomi T, Morimoto Y, Higashi T, Yasumoto K,. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg 1999; 67: 810-4.